December 25, 2014 6:33 PM ET

Healthcare Providers and Services

Company Overview of Mayo Clinic

Company Overview

Mayo Clinic, a not-for-profit medical group practice, provides medical care, research, and education services in Minnesota, Florida, Arizona, Iowa, Georgia, and Wisconsin. It offers medical care services in various specialties, including diabetes and endocrinology, gastroenterology, gynecology, cancer, neurology and neurosurgery, orthopedics, pulmonology, rheumatology, nephrology, urology, and cardiology and heart surgery. The company operates a network of care centers in the United States. It also provides medical education services through schools, offering various degree or certificate programs in continuing medical education, doctoral, master’s, and health sciences. In addition, the comp...

200 First Street SW

Rochester, MN 55905

United States

Founded in 1919

Phone:

507-284-2511

Fax:

507-284-0161

Key Executives for Mayo Clinic

Chief Executive Officer
Age: 62
Chief Financial Officer
Vice President
Age: 67
Vice President
Chief Administrative Officer
Compensation as of Fiscal Year 2014.

Mayo Clinic Key Developments

Mayo Clinic Announces Executive Changes

Mayo Clinic has appointed an attorney, Christina Zorn, as chief administrative officer and vice chair of administration at Mayo's Jacksonville campus. She will serve as administrative partner to Gianrico Farrugia, M.D., the incoming vice president of Mayo Clinic and CEO of the Jacksonville campus. Zorn begins work January 1, 2015. Zorn succeeds Robert Brigham, who has served as chief administrative officer in Florida since 2005. Brigham will retire from Mayo Clinic at the end of 2014.

The Mayo Clinic Appoints Mary Sue Coleman as New Public Member

The Mayo Clinic Board of Trustees appointed Mary Sue Coleman, Ph.D., as a new public member at its quarterly meeting held on Nov. 14, 2014. Dr. Coleman is president emeritus of the University of Michigan, (U-M) an institution she led for 12 years before retiring in July 2014.

GenomeDx Biosciences and Mayo Clinic Enter Agreement to Conduct Validation Study of Decipher Prostate Cancer Test in Patients Receiving Biopsy Prior to Treatment

GenomeDx Biosciences announced that the company has expanded its research agreement with Mayo Clinic to initiate a validation study to expand the use of the Decipher Prostate Cancer Classifier, a genomic test capable of predicting metastatic prostate cancer, for use in prostate biopsy specimens. The outcome of the study, if successful, is expected to support the application and utility of the Decipher test in patients receiving biopsy. The study is the result of research conducted by the Mayo Clinic Departments of Urology and Laboratory Medicine and Pathology. The study will be managed by Mayo Validation Support Services, which will serve as the collaboration liaison for the Mayo investigators while facilitating access to Mayo Clinic biospecimen resources and clinical information. GenomeDx and Mayo Clinic previously expanded their agreement in April 2013 to include an exclusive license to certain co-developed and Mayo-developed intellectual property. This new agreement includes continued access to the clinical data concerning Mayo Clinic's cohort of prostate cancer samples to allow for longer term follow-up and evaluation of biomarkers. The initial collaboration, entered in 2009, led to the development, validation, and commercialization of the Decipher Prostate Cancer Classifier for use in high-risk men following radical prostatectomy (prostate surgery). Decipher has already been validated in 10 peer-reviewed published studies, all work that was initiated with that initial Mayo collaboration. GenomeDx and Mayo Clinic previously expanded their agreement in April 2013 to include an exclusive license to certain co-developed and Mayo-developed intellectual property. This new agreement includes continued access to the clinical data concerning Mayo Clinic's cohort of prostate cancer samples to allow for longer term follow-up and evaluation of biomarkers. The initial collaboration, entered in 2009, led to the development, validation, and commercialization of the Decipher Prostate Cancer Classifier for use in high-risk men following radical prostatectomy (prostate surgery). Decipher has already been validated in 10 peer-reviewed published studies, all work that was initiated with that initial Mayo collaboration.

Similar Private Companies By Industry

Company Name Region
Vallar Consulting Corp. United States
The Independence ASC, LLC United States
Home Nursing Provider United States
Trident Emergency Physicians, L.L.C. United States
Thomas, Thomas & Walsh, Inc. United States

Recent Private Companies Transactions

Type
Date
Target
Private Placement
October 7, 2014
Second Genome, Inc.
Private Placement
July 3, 2014
DICOM Grid, Inc.
Private Placement
May 30, 2014
Chrono Therapeutics Inc.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
NYC2012, Inc. United States
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
Rush University United States
Greater Houston Partnership United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Mayo Clinic, please visit www.mayoclinic.org/patient-visitor-guide/minnesota. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.